ClinicalTrials.gg
RecruitingNCT07676903Updated Oct 5, 2026

A Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors

A Phase 1 interventional study of SHR-4685 in Solid Tumor, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 5, 2026First site in Australia5 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
170
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of SHR-4685 in participants with advanced solid tumors.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have fully understood this study and voluntarily signed the form, with good compliance and cooperation with follow-up;
  2. Age 18-75 years, any gender;
  3. Performance status score 0 or 1;
  4. Expected survival time greater than 3 months;
  5. Presence of at least one according to 1.1 criteria;
  6. Have adequate organ function;
  7. Female participants of must have a negative serum pregnancy test within 7 days prior to the first dose; and must not be lactating.

Exclusion criteria

Exclusion Criteria:

  1. Participants who have received any approved anti-tumor drugs (including anti-tumor drugs) within 4 weeks prior to the first dose of the IP;
  2. Toxicities from prior anti-tumor therapy have not recovered to ≤ Grade 1 or to the level specified in the inclusion/exclusion criteria;
  3. Presence of central nervous system (CNS) ;
  4. Concurrent active other than the primary tumor;
  5. History of central nervous system diseases within 12 months prior to screening;
  6. Participants who have undergone major surgery other than diagnostic or procedures within 28 days prior to the first dose, or who are expected to undergo major surgery during the study;
  7. Participants with active tuberculosis or a history of active tuberculosis infection within ≤48 weeks prior to screening, regardless of treatment;
  8. Presence of any significant clinical or laboratory abnormality that, in the investigator's opinion, affects safety evaluation;
  9. History of deep vein thrombosis or pulmonary embolism within 6 months prior to screening;
  10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring clinical intervention;
  11. Positive for (HIV) (HIV1/2 antibodies) with \<350 cells/uL; or history of other acquired/congenital immunodeficiency diseases; or history of allogeneic bone marrow or solid organ transplantation;
  12. Active chronic or active ;
  13. Known history of to any component of the formulations used in the study;
  14. Other factors, in the opinion of the investigator, that may affect the study results or result in forced halfway termination of this study, such as alcoholism, drug abuse, suffering from other serious diseases (including psychiatric disorders) requiring concomitant treatment, seriously abnormal laboratory test values, family or social factors and other conditions that may affect the safety of the patient or collection of study data.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    SHR-4685 group

    Participants will receive SHR-4685 in different doses.

    Drug: SHR-4685

Interventions

  • DrugSHR-4685

    SHR-4685, in different doses.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT) of SHR-4685.

    Time frame: Up to 21 days.

  2. Maximum tolerated dose (MTD) of SHR-4685.

    Time frame: Up to 24 months.

  3. Recommended Phase II Dose (RP2D) of SHR-4685.

    Time frame: Up to 24 months.

  4. Adverse events (AEs).

    Time frame: From the first drug administration to within 30 days for the last treatment dose, up to 24 months.

  5. Serious adverse events (SAEs).

    Time frame: From the first drug administration to within 30 days for the last treatment dose, up to 24 months.

Secondary outcomes

  1. The concentration of SHR-4685 in plasma will be determined.

    Cmax will be derived.

    Time frame: At predefined intervals throughout the treatment period, up to 24 months.

  2. Time to maximum concentration (Tmax).

    Evaluation of pharmacokinetic parameter of SHR-4685.

    Time frame: At predefined intervals throughout the treatment period, up to 24 months.

  3. Area under the concentration-time curve from time 0 to time t (time of the last measurable concentration) (AUC0-t).

    Evaluation of pharmacokinetic parameter of SHR-4685. The concentration of SHR-4685 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.

    Time frame: At predefined intervals throughout the treatment period, up to 24 months.

  4. The concentration of Anti-SHR-4685 antibodies (ADA) in plasma will be determined.

    Time frame: At predefined intervals throughout the treatment period, up to 24 months.

  5. Objective Response Rate (ORR).

    Complete Response (CR) and Partial Response (PR) based on RECIST 1.1.

    Time frame: Up to 24 months.

  6. Disease control rate (DCR).

    Complete Response (CR), Partial Response (PR) and Stable Disease (SD) based on RECIST 1.1.

    Time frame: Up to 24 months.

  7. Duration of response (DoR).

    Time from documentation of tumor response to disease progression assessed among patients who had an objective response.

    Time frame: Up to 24 months.

  8. Progression Free Survival (PFS).

    Time from C1D1 to first assessment of disease progression or death, whichever is earlier.

    Time frame: Up to 24 months.

07

Study locations

1 of 6 sites recruiting
  • Macquarie University Hospital
    North Ryde, New South Wales 2109, Australia
    Not yet recruiting
    • Andrew Parsonson, Dr · Principal investigator
  • GenesisCare North Shore
    St Leonards, New South Wales 2065, Australia
    Not yet recruiting
    • Nick Pavlakis, Dr · Principal investigator
  • Icon Cancer Centre South Brisbane
    South Brisbane, Queensland 4101, Australia
    Not yet recruiting
    • Jermaine Coward, A/Prof · Principal investigator
  • Cancer Research SA
    Adelaide, South Australia 5000, Australia
    Not yet recruiting
    • Chen Yong, Dr · Principal investigator
  • Epworth HealthCare - Richmond
    Richmond, Victoria 3121, Australia
    Not yet recruiting
    • Ross Jennens, Dr · Principal investigator
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Oct 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jun 30, 2026
StartActual
Aug 13, 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added — first site in Australia
Show 5 added (5 Australia)
  • Macquarie University Hospital · North Ryde, Australia
  • GenesisCare North Shore · St Leonards, Australia
  • Icon Cancer Centre South Brisbane · South Brisbane, Australia
  • Cancer Research SA · Adelaide, Australia
  • Epworth HealthCare - Richmond · Richmond, Australia
Oct 5, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Beijing Cancer Hospital · Beijing, ChinaContact removed d•••@sina.cn · •••6561Contact removed (no phone or email listed)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    5 sites added — first site in Australia
    Show 5 added (5 Australia)
    • Macquarie University Hospital · North Ryde, Australia
    • GenesisCare North Shore · St Leonards, Australia
    • Icon Cancer Centre South Brisbane · South Brisbane, Australia
    • Cancer Research SA · Adelaide, Australia
    • Epworth HealthCare - Richmond · Richmond, Australia
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Beijing Cancer Hospital · Beijing, ChinaContact removed d•••@sina.cn · •••6561Contact removed (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07676903
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Aug 13, 2026
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Ran Zhao, M.D
Contact
ran.zhao.rz7@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion